奥翔药业 (603229)
Zhejiang Ausun Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 83029.71
- Circulating A-Shares(W): 83029.71
- Earnings Per Share(RMB): 0.2500
- Net Assets Per Share(RMB): 2.8271
- Operating Revenue(W RMB): 64596.16
- Total Profit(W RMB): 23334.57
- **Net Profit Attributable to Parent(W RMB) **: 20703.19
- Net Profit Growth Rate(%): -9.59
- Weighted Return on Equity(%): 8.8600
- Operating Cash Flow Per Share(RMB): 0.1780
- Undistributed Profit Per Share(RMB): 1.2016
- Capital Reserve Per Share(RMB): 0.5302
2. Main Business
The main business covers:
- Research, development, production, and sales of specialty active pharmaceutical ingredients (APIs) and pharmaceutical intermediates
- Providing customers with contract manufacturing and research and development services
3. Company Basic Information
- Company Name: Zhejiang Ausun Pharmaceutical Co., Ltd.
- Listing Date: 2017-05-09
- Industry: Pharmaceutical Manufacturing
- Address: No. 5 Donghai Fourth Avenue, Linhai Park, Zhejiang Chemical API Base, Zhejiang Province
- Website: https://www.ausunpharm.com/
- Company Profile: The issuer was established by the overall change of Zhejiang Ausun Pharmaceutical Co., Ltd. into a joint stock company. On November 30, 2014, Zhejiang Ausun Pharmaceutical Co., Ltd. held an interim shareholders' meeting and approved the overall change into a joint stock company. According to the Tianjian Auditing [2014] No. 6555 "Audit Report" issued by Tianjian Certified Public Accountants (Special General Partnership), as of the audit base date October 31, 2014, the audited net assets of Ausun Co., Ltd. were RMB 62,627,592.18, of which RMB 46,500,000.00 was used as the registered capital of the changed joint stock company, and the remaining RMB 16,127,592.18 was used as the capital reserve of the joint stock company. Tianjian Certified Public Accountants (Special General Partnership) verified the capital contribution and issued the Tianjian Verification [2014] No. 286 "Capital Verification Report". On December 18, 2014, the company completed the industrial and commercial change registration procedures at the Taizhou Administration for Market Regulation and obtained the Business License with registration number 331082000047854, with a registered capital of RMB 46.5 million. After the capital increase and expansion in March 2015, the conversion of capital reserve into share capital in December 2015, and the conversion of capital reserve into share capital and distribution of undistributed profits as shares in November 2016, the company's current registered capital is RMB 120 million. On November 28, 2016, the company completed the industrial and commercial change registration procedures at the Taizhou Administration for Market Regulation and obtained the Business License with Unified Social Credit Code 91331000554754592X.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Jiaxing Aoxiang Equity Investment Management Partnership (Limited Partnership) | Corporate Entity | 1543.47 | 1.86 |
| 2 | Shanghai Duxi Bingtai Private Fund Management Co., Ltd. - Bingtai Long-term Dividend No. 1 Private Securities Investment Fund | Private Securities Investment Fund | 906.09 | 1.09 |
| 3 | Taizhou Financial Holding Asset Management Co., Ltd. | Corporate Entity | 797.75 | 0.96 |
| 4 | Jiaxing Zhongxiang Equity Investment Management Partnership (Limited Partnership) | Corporate Entity | 771.70 | 0.93 |
| 5 | Shanghai Duxi Bingtai Private Fund Management Co., Ltd. - Duxi Pharmaceutical Growth Private Securities Investment Fund | Private Securities Investment Fund | 755.50 | 0.91 |
| 6 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 535.57 | 0.65 |
5. Concept Sectors
- CXO Concept
- Hepatitis Concept
- Innovative Drugs
- Margin Trading & Securities Lending
- Share Repurchase Plan
- SSE 380 Index
Remarks
- Data update date: 2025-09-30
- Data source: Public Market Information